Merck (MRK) Announces European Commission Approves KEYTRUDA Plus LENVIMA for Patients With Certain Types of Endometrial Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to Merck (MRK) Announces European Commission Approves KEYTRUDA Plus LENVIMA for Patients With Certain Types of Endometrial Carcinoma

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma

November 29, 2021 6:50 AM EST

First Combination of Immunotherapy With Tyrosine Kinase Inhibitor Approved in Europe for Adult Patients With Advanced or Recurrent Endometrial Carcinoma With Disease Progression on or Following Prior Treatment With a Platinum-Containing Therapy in Any Setting and Who Are Not Candidates for Curative Surgery or Radiation 

Approval Based on KEYNOTE-775/Study 309 Results... More